Browse the evidence

The most frequent adverse events associated with retatrutide were gastrointestinal, including nausea, diarrhea, and vomiting.

Clinicians should monitor for gastrointestinal side effects when prescribing retatrutide.

The approval of semaglutide by the FDA was based on the results of clinical trials.

Practitioners can inform patients that semaglutide is FDA-approved for weight management based on clinical evidence.

The cohort of 618 participants was successfully recruited despite challenges, exceeding the target of 600.

Successful recruitment strategies can be applied to similar trials.

The incidence of gastrointestinal adverse effects with tirzepatide was similar to that of semaglutide.

Tirzepatide may have a similar safety profile regarding gastrointestinal effects compared to semaglutide.

Four nights of sleep restriction did not alter resting energy metabolism in postmenopausal women.

Practitioners can note that while insulin sensitivity and fat oxidation are affected, resting metabolism remains stable with sleep restriction.

Allowing Medicare coverage of anti-obesity medications could increase annual Part D costs by $3.1 billion or $6.1 billion depending on the percentage of newly eligible patients prescribed the drugs.

Practitioners should be aware of the potential financial implications of Medicare coverage for anti-obesity medications.

The marginal costs of Medicare coverage for anti-obesity drugs could decrease by up to 62.5% if products are approved for additional indications.

Practitioners should consider the potential for reduced costs if additional indications for anti-obesity drugs are approved.

The policy change of covering anti-obesity medications is likely to increase Medicare costs by low to middle tens of billions of dollars over ten years.

Practitioners should prepare for the potential long-term financial impact of Medicare's coverage of anti-obesity medications.

Nose-to-brain (N2B) pathways can address limitations of the subcutaneous route for GLP-1 RAs.

Practitioners should explore N2B pathways as a viable alternative for delivering GLP-1 RAs.

There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.

HU6 may not improve cardiovascular function despite weight loss.

25,215 adverse event reports related to tirzepatide were identified, predominantly in the 65 to 85 age group.

Healthcare providers should be aware of the high volume of AE reports in older adults using tirzepatide.

Novel adverse event signals include thyroid mass, medullary thyroid carcinoma, and conditions affecting the reproductive system and breast.

Clinicians should be vigilant for these specific adverse events in patients treated with tirzepatide.

The need for more effective treatments for obesity is obvious due to the far-reaching effects of the condition.

Healthcare providers should prioritize finding effective obesity treatments.

Ingestion of deuterated water results in 2 H enrichment of the body water pool, which is incorporated into tissue proteins.

This highlights a novel approach to studying protein synthesis in muscle tissue.

There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.

Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.

The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.

Awareness of the obesity epidemic is crucial for public health initiatives.

The most common adverse events associated with semaglutide are gastrointestinal in nature.

Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing semaglutide.

Ex-DARPin fusion proteins injected at 25 nmol/kg every three days significantly lowered blood glucose, inhibited food consumption, and reduced body weight for 30 days in STZ-induced diabetic mice.

Ex-DARPin fusion proteins may be a promising treatment for managing blood glucose and weight in diabetic patients.

Ex-DARPin fusion proteins have a comparable half-life of 29-32 hours, which is much longer than that of native Ex (0.5 hours in rats).

Longer half-life of Ex-DARPin fusion proteins may reduce the frequency of administration needed for effective treatment.

Ex-DARPin fusion proteins significantly improved the survival of pancreatic islets in diabetic mice.

Improving pancreatic islet survival could enhance insulin production and overall diabetes management.

There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.

Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.

30% of steep losers died during postintervention follow-up versus 10-18% in other trajectories.

Monitoring for excessive weight loss is crucial, especially in older adults with diabetes.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.

Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.